Table 2.

Subsequent treatment (N = 88)

Subsequent treatment	n (%)
Received subsequent therapy	26 (29.5)
Avelumab	4 (4.5)
Carboplatin + etoposide	4 (4.5)
Pembrolizumab	4 (4.5)
Everolimus	3 (3.4)
Nivolumab	3 (3.4)
Pazopanib	3 (3.4)
Capecitabine	2 (2.3)
Cyclophosphamide + doxorubicin + vincristine	2 (2.3)
Paclitaxel	2 (2.3)
Pegylated liposomal doxorubicin hydrochloride	2 (2.3)
Temozolomide	2 (2.3)
Topotecan	2 (2.3)
Amrubicin	1 (1.1)
Carboplatin	1 (1.1)
Carboplatin + paclitaxel	1 (1.1)
Cisplatin	1 (1.1)
Combinations of antineoplastic agents	1 (1.1)
Cyclophosphamide	1 (1.1)
Ipilimumab + nivolumab	1 (1.1)
Octreotide	1 (1.1)
Sunitinib	1 (1.1)
Somatostatin	1 (1.1)
Other therapeutic product	1 (1.1)